Diabetic dyslipidemia

Metabolism: Clinical and Experimental

Volumn 63, Issue 12, 2014, Pages 1469-1479

  Wu, Liya ^b   Parhofer, Klaus G ^a  

^a UNIVERSITY OF MUNICH   (Germany)

^b NONE

Author keywords

Hyperlipoproteinemia; Hypertriglyceridemia; Mixed dyslipidemia; Postprandial

Indexed keywords

ANTIDIABETIC AGENT; BILE ACID SEQUESTRANT; FIBRIC ACID DERIVATIVE; HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE INHIBITOR; HYPOCHOLESTEROLEMIC AGENT; NICOTINIC ACID; OMEGA 3 FATTY ACID;

CARDIOVASCULAR DISEASE; DIABETES MELLITUS; DIET THERAPY; DISEASE ASSOCIATION; DYSLIPIDEMIA; HUMAN; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; CARDIOVASCULAR DISEASES; DYSLIPIDEMIAS; METABOLISM;

CARDIOVASCULAR DISEASES; DIABETES COMPLICATIONS; DYSLIPIDEMIAS; HUMANS;

EID: 84925227145     PISSN: 00260495     EISSN: 15328600     Source Type: Journal    
DOI: 10.1016/j.metabol.2014.08.010     Document Type: Review

References (100)

1. Center for Disease Control, Prevention National diabetes fact sheet Accessed at http://www.cdc.gov/diabetes/pubs/pdf/ndfs-2011.pdf 2011 [on 30.11.2013]
2. Action to Control Cardiovascular Risk in Diabetes Study G, H.C. Gerstein, and M.E. Miller Effects of intensive glucose lowering in type 2 diabetes N Engl J Med 24 2008 2545 2559
3. M. Arca, G. Pigna, and C. Favoccia Mechanisms of diabetic dyslipidemia: relevance for atherogenesis Curr Vasc Pharmacol 10 6 2012 684 686
4. C. Lorenzo, S. Hartnett, and A.J. Hanley Impaired fasting glucose and impaired glucose tolerance have distinct lipoprotein and apolipoprotein changes: the insulin resistance atherosclerosis study J Clin Endocrinol Metab 98 4 2013 1622 1630
5. M. Adiels, S.O. Olofsson, and M.R. Taskinen Overproduction of very low-density lipoproteins is the hallmark of the dyslipidemia in the metabolic syndrome Arterioscler Thromb Vasc Biol 28 7 2008 1225 1236
6. R.K. Avramoglu, H. Basciano, and K. Adeli Lipid and lipoprotein dysregulation in insulin resistant states Clin Chim Acta 368 1-2 2006 1 19
7. M. Ensling, W. Steinmann, and A. Whaley-Connell Hypoglycemia: a possible link between insulin resistance, metabolic dyslipidemia, and heart and kidney disease (the cardiorenal syndrome) Cardiorenal Med 1 1 2011 67 74
8. M. Adiels, J. Boren, and M.J. Caslake Overproduction of VLDL1 driven by hyperglycemia is a dominant feature of diabetic dyslipidemia Arterioscler Thromb Vasc Biol 25 8 2005 1697 1703
9. J. Saleh, A.D. Sniderman, and K. Cianflone Regulation of plasma fatty acid metabolism Clin Chim Acta 286 1-2 1999 163 180
10. A. Kawakami, and M. Yoshida Apolipoprotein CIII links dyslipidemia with atherosclerosis J Atheroscler Thromb 16 1 2009 6 11
11. S. Caron, A. Verrijken, and I. Mertens Transcriptional activation of apolipoprotein CIII expression by glucose may contribute to diabetic dyslipidemia Arterioscler Thromb Vasc Biol 31 3 2011 513 519
12. Tg, Hdl Working Group of the Exome Sequencing Project NHL, and I. Blood Loss-of-function mutations in APOC3, triglycerides, and coronary disease N Engl J Med 371 1 2014 22 31
13. A.B. Jorgensen, R. Frikke-Schmidt, and B.G. Nordestgaard Loss-of-function mutations in APOC3 and risk of ischemic vascular disease N Engl J Med 371 1 2014 32 41
14. H. Duez, B. Lamarche, and K.D. Uffelman Hyperinsulinemia is associated with increased production rate of intestinal apolipoprotein B-48-containing lipoproteins in humans Arterioscler Thromb Vasc Biol 26 6 2006 1357 1363
15. J.C. Hogue, B. Lamarche, and A.J. Tremblay Evidence of increased secretion of apolipoprotein B-48-containing lipoproteins in subjects with type 2 diabetes J Lipid Res 48 6 2007 1336 1342
16. C. Xiao, and G.F. Lewis Regulation of chylomicron production in humans Biochim Biophys Acta 1821 5 2012 736 746
17. C. Xiao, S. Dash, and C. Morgantini Novel role of enteral monosaccharides in intestinal lipoprotein production in healthy humans Arterioscler Thromb Vasc Biol 33 5 2013 1056 1062
18. W. Tsuang, U. Navaneethan, and L. Ruiz Hypertriglyceridemic pancreatitis: presentation and management Am J Gastroenterol 104 4 2009 984 991
19. A. Lennertz, K.G. Parhofer, and W. Samtleben Therapeutic plasma exchange in patients with chylomicronemia syndrome complicated by acute pancreatitis Ther Apher 3 3 1999 227 233
20. M. Guerin, W. Le Goff, and T.S. Lassel Atherogenic role of elevated CE transfer from HDL to VLDL(1) and dense LDL in type 2 diabetes: impact of the degree of triglyceridemia Arterioscler Thromb Vasc Biol 21 2 2001 282 288
21. K.K. Berneis, and R.M. Krauss Metabolic origins and clinical significance of LDL heterogeneity J Lipid Res 43 9 2002 1363 1379
22. D.C. Chan, A. Hoang, and P.H. Barrett Apolipoprotein B-100 and apoA-II kinetics as determinants of cellular cholesterol efflux J Clin Endocrinol Metab 97 9 2012 E1658 E1666
23. B.G. Drew, K.A. Rye, and S.J. Duffy The emerging role of HDL in glucose metabolism Nat Rev Endocrinol 8 4 2012 237 245
24. L.R. Brunham, J.K. Kruit, and C.B. Verchere Cholesterol in islet dysfunction and type 2 diabetes J Clin Invest 118 2 2008 403 408
25. S. Shah, J.P. Casas, and F. Drenos Causal relevance of blood lipid fractions in the development of carotid atherosclerosis: Mendelian randomization analysis Circ Cardiovasc Genet 6 1 2013 63 72
26. R. Do, C.J. Willer, and E.M. Schmidt Common variants associated with plasma triglycerides and risk for coronary artery disease Nat Genet 45 11 2013 1345 1352
27. C.C. Cowie, B.V. Howard, and M.I. Harris Serum lipoproteins in African Americans and whites with non-insulin-dependent diabetes in the US population Circulation 90 3 1994 1185 1193
28. M.A. Austin, and K.L. Edwards Small, dense low density lipoproteins, the insulin resistance syndrome and noninsulin-dependent diabetes Curr Opin Lipidol 7 3 1996 167 171
29. R. Carmena, P. Duriez, and J.C. Fruchart Atherogenic lipoprotein particles in atherosclerosis Circulation 109 23 Suppl 1 2004 III2 III7
30. B.V. Howard, D.C. Robbins, and M.L. Sievers LDL cholesterol as a strong predictor of coronary heart disease in diabetic individuals with insulin resistance and low LDL: the Strong Heart Study Arterioscler Thromb Vasc Biol 20 3 2000 830 835
31. M. Miller, N.J. Stone, and C. Ballantyne Triglycerides and cardiovascular disease: a scientific statement from the American Heart Association Circulation 123 20 2011 2292 2333
32. A. Varbo, M. Benn, and A. Tybjaerg-Hansen Remnant cholesterol as a causal risk factor for ischemic heart disease J Am Coll Cardiol 61 4 2013 427 436
33. W.P. Castelli, R.J. Garrison, and P.W. Wilson Incidence of coronary heart disease and lipoprotein cholesterol levels. The Framingham Study JAMA 256 20 1986 2835 2838
34. G. Assmann, H. Schulte, and A. von Eckardstein High-density lipoprotein cholesterol as a predictor of coronary heart disease risk. The PROCAM experience and pathophysiological implications for reverse cholesterol transport Atherosclerosis 124 Suppl 1996 S11 S20
35. A. von Eckardstein, J.R. Nofer, and G. Assmann High density lipoproteins and arteriosclerosis. Role of cholesterol efflux and reverse cholesterol transport Arterioscler Thromb Vasc Biol 21 1 2001 13 27
36. W. Annema, and A. von Eckardstein High-density lipoproteins. Multifunctional but vulnerable protections from atherosclerosis Circ J 77 10 2013 2432 2448
37. B.F. Voight, G.M. Peloso, and M. Orho-Melander Plasma HDL cholesterol and risk of myocardial infarction: a mendelian randomisation study Lancet 380 9841 2012 572 580
38. C.R. Sirtori, L. Calabresi, and G. Franceschini Cardiovascular status of carriers of the apolipoprotein A-I (Milano) mutant: the Limone sul Garda study Circulation 103 15 2001 1949 1954
39. P.J. Barter, M. Caulfield, and M. Eriksson Effects of torcetrapib in patients at high risk for coronary events N Engl J Med 357 21 2007 2109 2122
40. T.F. Luscher, U. Landmesser, and A. von Eckardstein High-density lipoprotein: vascular protective effects, dysfunction, and potential as therapeutic target Circ Res 114 1 2014 171 182
41. American Diabetes A Standards of medical care in diabetes - 2013 Diabetes Care 36 Suppl 1 2013 S11 S66
42. Authors/Task Force M, L. Ryden, and P.J. Grant ESC guidelines on diabetes, pre-diabetes, and cardiovascular diseases developed in collaboration with the EASD: the Task Force on diabetes, pre-diabetes, and cardiovascular diseases of the European Society of Cardiology (ESC) and developed in collaboration with the European Association for the Study of Diabetes (EASD) Eur Heart J 34 39 2013 3035 3087
43. N.J. Stone, J. Robinson, and A.H. Lichtenstein ACC/AHA guideline on the treatment of blood cholesterol to reduce atherosclerotic cardiovascular risk in adults: a report of the American College of Cardiology/American Heart Association Task Force on Practice Guidelines J Am Coll Cardiol 2013 2013
44. E. Ingelsson, E.J. Schaefer, and J.H. Contois Clinical utility of different lipid measures for prediction of coronary heart disease in men and women JAMA 298 7 2007 776 785
45. R. Jiang, M.B. Schulze, and T. Li Non-HDL cholesterol and apolipoprotein B predict cardiovascular disease events among men with type 2 diabetes Diabetes Care 27 8 2004 1991 1997
46. J.D. Brunzell, M. Davidson, and C.D. Furberg Lipoprotein management in patients with cardiometabolic risk: consensus statement from the American Diabetes Association and the American College of Cardiology Foundation Diabetes Care 31 4 2008 811 822
47. J.M. Chehade, M. Gladysz, and A.D. Mooradian Dyslipidemia in type 2 diabetes: prevalence, pathophysiology, and management Drugs 73 4 2013 327 339
48. D.S. Bell, F. Al Badarin, and J.H. O'Keefe Jr. Therapies for diabetic dyslipidaemia Diabetes Obes Metab 13 4 2011 313 325
49. S. Klein, N.F. Sheard, and X. Pi-Sunyer Weight management through lifestyle modification for the prevention and management of type 2 diabetes: rationale and strategies. A statement of the American Diabetes Association, the North American Association for the Study of Obesity, and the American Society for Clinical Nutrition Am J Clin Nutr 80 2 2004 257 263
50. R.R. Wing, W. Lang, and T.A. Wadden Benefits of modest weight loss in improving cardiovascular risk factors in overweight and obese individuals with type 2 diabetes Diabetes Care 34 7 2011 1481 1486
51. A.R.G. Look, R.R. Wing, and P. Bolin Cardiovascular effects of intensive lifestyle intervention in type 2 diabetes N Engl J Med 369 2 2013 145 154
52. A.B. Evert, J.L. Boucher, and M. Cypress Nutrition therapy recommendations for the management of adults with diabetes Diabetes Care 36 11 2013 3821 3842
53. R. Estruch, E. Ros, and J. Salas-Salvado Primary prevention of cardiovascular disease with a Mediterranean diet N Engl J Med 368 14 2013 1279 1290
54. Y. Bao, J. Han, and F.B. Hu Association of nut consumption with total and cause-specific mortality N Engl J Med 369 21 2013 2001 2011
55. L. Wu, K. Piotrowski, and T. Rau Walnut-enriched diet reduces fasting non-HDL-cholesterol and apolipoprotein B in healthy Caucasian subjects: a randomized controlled cross-over clinical trial Metabolism 63 3 2014 382 391
56. J. Sabate, K. Oda, and E. Ros Nut consumption and blood lipid levels: a pooled analysis of 25 intervention trials Arch Intern Med 170 9 2010 821 827
57. D.J. Jenkins, C.W. Kendall, and M.S. Banach Nuts as a replacement for carbohydrates in the diabetic diet Diabetes Care 34 8 2011 1706 1711
58. E. Ros, and F.B. Hu Consumption of plant seeds and cardiovascular health: epidemiological and clinical trial evidence Circulation 128 5 2013 553 565
59. G. Riccardi, and A.A. Rivellese Effects of dietary fiber and carbohydrate on glucose and lipoprotein metabolism in diabetic patients Diabetes Care 14 12 1991 1115 1125
60. L. Brown, B. Rosner, and W.W. Willett Cholesterol-lowering effects of dietary fiber: a meta-analysis Am J Clin Nutr 69 1 1999 30 42
61. O. Ajala, P. English, and J. Pinkney Systematic review and meta-analysis of different dietary approaches to the management of type 2 diabetes Am J Clin Nutr 97 3 2013 505 516
62. I. Shai, D. Schwarzfuchs, and Y. Henkin Weight loss with a low-carbohydrate, Mediterranean, or low-fat diet N Engl J Med 359 3 2008 229 241
63. C.M. Kastorini, H.J. Milionis, and K. Esposito The effect of Mediterranean diet on metabolic syndrome and its components: a meta-analysis of 50 studies and 534,906 individuals J Am Coll Cardiol 57 11 2011 1299 1313
64. M. Rizzo, A.A. Rizvi, and G.A. Spinas Glucose lowering and anti-atherogenic effects of incretin-based therapies: GLP-1 analogues and DPP-4-inhibitors Expert Opin Investig Drugs 18 10 2009 1495 1503
65. K.G. Parhofer, C. Otto, and H.C. Geiss Effect of pioglitazone on lipids in well controlled patients with diabetes mellitus type 2 - results of a pilot study Exp Clin Endocrinol Diabetes 113 1 2005 49 52
66. A.M. Lincoff, J.C. Tardif, and G.G. Schwartz Effect of aleglitazar on cardiovascular outcomes after acute coronary syndrome in patients with type 2 diabetes mellitus: the AleCardio randomized clinical trial JAMA 311 15 2014 1515 1525
67. Cholesterol Treatment Trialists C, P.M. Kearney, and L. Blackwell Efficacy of cholesterol-lowering therapy in 18,686 people with diabetes in 14 randomised trials of statins: a meta-analysis Lancet 371 9607 2008 117 125
68. A.S. Group, H.N. Ginsberg, and M.B. Elam Effects of combination lipid therapy in type 2 diabetes mellitus N Engl J Med 362 17 2010 1563 1574
69. O.T. Investigators, J. Bosch, and H.C. Gerstein n-3 fatty acids and cardiovascular outcomes in patients with dysglycemia N Engl J Med 367 4 2012 309 318
70. The Lipid Research Clinics Coronary Primary Prevention Trial results. I. Reduction in incidence of coronary heart disease JAMA 251 3 1984 351 364
71. The Lipid Research Clinics Coronary Primary Prevention Trial results. II. The relationship of reduction in incidence of coronary heart disease to cholesterol lowering JAMA 251 3 1984 365 374
72. A.-H. Investigators, W.E. Boden, and J.L. Probstfield Niacin in patients with low HDL cholesterol levels receiving intensive statin therapy N Engl J Med 365 24 2011 2255 2267
73. HTC Group HPS2-THRIVE randomized placebo-controlled trial in 25 673 high-risk patients of ER niacin/laropiprant: trial design, pre-specified muscle and liver outcomes, and reasons for stopping study treatment Eur Heart J 34 17 2013 1279 1291
74. J. Davignon Beneficial cardiovascular pleiotropic effects of statins Circulation 109 23 Suppl 1 2004 III39 III43
75. H.M. Colhoun, D.J. Betteridge, and P.N. Durrington Primary prevention of cardiovascular disease with atorvastatin in type 2 diabetes in the Collaborative Atorvastatin Diabetes Study (CARDS): multicentre randomised placebo-controlled trial Lancet 364 9435 2004 685 696
76. U.K. Sampson, S. Fazio, and M.F. Linton Residual cardiovascular risk despite optimal LDL cholesterol reduction with statins: the evidence, etiology, and therapeutic challenges Curr Atheroscler Rep 14 1 2012 1 10
77. N. Sattar, D. Preiss, and H.M. Murray Statins and risk of incident diabetes: a collaborative meta-analysis of randomised statin trials Lancet 375 9716 2010 735 742
78. B.D. Henriksbo, T.C. Lau, and J.F. Cavallari Fluvastatin causes NLRP3 inflammasome-mediated adipose insulin resistance Diabetes 2014 [Advance online publication. pii: DB-131398]
79. C.M. Rotella, A. Zaninelli, and C. Le Grazie Ezetimibe/simvastatin vs simvastatin in coronary heart disease patients with or without diabetes Lipids Health Dis 9 2010 80
80. L. Bozzetto, G. Annuzzi, and G.D. Corte Ezetimibe beneficially influences fasting and postprandial triglyceride-rich lipoproteins in type 2 diabetes Atherosclerosis 217 1 2011 142 148
81. M. Lee, J.L. Saver, and A. Towfighi Efficacy of fibrates for cardiovascular risk reduction in persons with atherogenic dyslipidemia: a meta-analysis Atherosclerosis 217 2 2011 492 498
82. G. Reyes-Soffer, C.I. Ngai, and L. Lovato Effect of combination therapy with fenofibrate and simvastatin on postprandial lipemia in the ACCORD lipid trial Diabetes Care 36 2 2013 422 428
83. S. Bellosta, R. Paoletti, and A. Corsini Safety of statins: focus on clinical pharmacokinetics and drug interactions Circulation 109 23 Suppl 1 2004 III50 III57
84. J. Pang, D.C. Chan, and S.J. Hamilton Effect of niacin on high-density lipoprotein apolipoprotein A-I kinetics in statin-treated patients with type 2 diabetes mellitus Arterioscler Thromb Vasc Biol 34 2 2014 427 432
85. Results from HPS2-THRIVE Study of TREDAPTIVE (extended-release niacin/laropiprant) presented at American College of Cardiology Scientific Sessions Accessed at http://www.mercknewsroom.com/press-release/research-and-development-news/results-hps2-thrive-study-tredaptive-extended-release-ni [on 30.11.2013]
86. B. Staels, and V.A. Fonseca Bile acids and metabolic regulation: mechanisms and clinical responses to bile acid sequestration Diabetes Care 32 Suppl 2 2009 S237 S245
87. J. Rosenstock, S.P. Rigby, and D.M. Ford The glucose and lipid effects of colesevelam as monotherapy in drug-naive type 2 diabetes Horm Metab Res 46 5 2014 348 353
88. O.M. Nwose, and M.R. Jones Atypical mechanism of glucose modulation by colesevelam in patients with type 2 diabetes Clin Med Insights Endocrinol Diabetes 6 2013 75 79
89. D. Swanson, R. Block, and S.A. Mousa Omega-3 fatty acids EPA and DHA: health benefits throughout life Adv Nutr 3 1 2012 1 7
90. T. Teramoto, M. Shirakawa, and M. Kikuchi Efficacy and safety of the cholesteryl ester transfer protein inhibitor anacetrapib in Japanese patients with dyslipidemia Atherosclerosis 230 1 2013 52 60
91. S.J. Nicholls, H.B. Brewer, and J.J. Kastelein Effects of the CETP inhibitor evacetrapib administered as monotherapy or in combination with statins on HDL and LDL cholesterol: a randomized controlled trial JAMA 306 19 2011 2099 2109
92. E.A. Stein, R. Dufour, and C. Gagne Apolipoprotein B synthesis inhibition with mipomersen in heterozygous familial hypercholesterolemia: results of a randomized, double-blind, placebo-controlled trial to assess efficacy and safety as add-on therapy in patients with coronary artery disease Circulation 126 19 2012 2283 2292
93. M. Cuchel, E.A. Meagher, and Theron H. du Toit Efficacy and safety of a microsomal triglyceride transfer protein inhibitor in patients with homozygous familial hypercholesterolaemia: a single-arm, open-label, phase 3 study Lancet 381 9860 2013 40 46
94. D.J. Blom, T. Hala, and M. Bolognese A 52-week placebo-controlled trial of evolocumab in hyperlipidemia N Engl J Med 370 19 2014 1809 1819
95. N.R. Desai, P. Kohli, and R.P. Giugliano AMG145, a monoclonal antibody against proprotein convertase subtilisin kexin type 9, significantly reduces lipoprotein(a) in hypercholesterolemic patients receiving statin therapy: an analysis from the LDL-C Assessment with Proprotein Convertase Subtilisin Kexin Type 9 Monoclonal Antibody Inhibition Combined with Statin Therapy (LAPLACE)-Thrombolysis in Myocardial Infarction (TIMI) 57 trial Circulation 128 9 2013 962 969
96. E.A. Stein, S. Mellis, and G.D. Yancopoulos Effect of a monoclonal antibody to PCSK9 on LDL cholesterol N Engl J Med 366 12 2012 1108 1118
97. M.J. Graham, R.G. Lee, and T.A. Bell III Antisense oligonucleotide inhibition of apolipoprotein C-III reduces plasma triglycerides in rodents, nonhuman primates, and humans Circ Res 112 11 2013 1479 1490
98. D.L. Dixon, E.M. Sisson, and M. Butler Lomitapide and mipomersen: novel lipid-lowering agents for the management of familial hypercholesterolemia J Cardiovasc Nurs 29 5 2014 E7 E12
99. J.C. Cohen, E. Boerwinkle, and T.H. Mosley Jr. Sequence variations in PCSK9, low LDL, and protection against coronary heart disease N Engl J Med 354 12 2006 1264 1272
100. G.F. Watts, S. Gidding, and A.S. Wierzbicki Integrated guidance on the care of familial hypercholesterolaemia from the International FH Foundation Int J Cardiol 171 3 2014 309 325